Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Baggelaar, M."'
Autor:
Mukhopadhyay, P., Baggelaar, M., Erdelyi, K., Cao, Z., Cinar, R., Fezza, F., Ignatowska-Jankowska, B., Wilkerson, J., Gils, N. van, Hansen, T., Ruben, M., Soethoudt, M., Heitman, L., Kunos, G., Maccarrone, M., Lichtman, A., Pacher, P., Stelt, M. van der
Publikováno v:
Mukhopadhyay, P, Baggelaar, M, Erdelyi, K, Cao, Z, Cinar, R, Fezza, F, Ignatowska-Janlowska, B, Wilkerson, J, van Gils, N, Hansen, T, Ruben, M, Soethoudt, M, Heitman, L, Kunos, G, Maccarrone, M, Lichtman, A, Pacher, P & Van der Stelt, M 2016, ' The novel, orally available and peripherally restricted selective cannabinoid CB2 receptor agonist LEI-101 prevents cisplatin-induced nephrotoxicity ', British Journal of Pharmacology, vol. 173, no. 3, pp. 446-58 . https://doi.org/10.1111/bph.13338
British Journal of Pharmacology, 173(3), 446-458. Wiley-Blackwell
Mukhopadhyay, P, Baggelaar, M, Erdelyi, K, Cao, Z, Cinar, R, Fezza, F, Ignatowska-Janlowska, B, Wilkerson, J, Van Gils, N, Hansen, T, Ruben, M, Soethoudt, M, Heitman, L, Kunos, G, Maccarrone, M, Lichtman, A, Pacher, P & Van Der Stelt, M 2016, ' The novel, orally available and peripherally restricted selective cannabinoid CB 2 receptor agonist LEI-101 prevents cisplatin-induced nephrotoxicity ', British Journal of Pharmacology, vol. 173, no. 3, pp. 446-458 . https://doi.org/10.1111/bph.13338
British Journal of Pharmacology, 173(3), 446-58. Wiley-Blackwell
British Journal of Pharmacology, 173(3), 446–458
British Journal of Pharmacology, 173(3), 446-458. Wiley-Blackwell
Mukhopadhyay, P, Baggelaar, M, Erdelyi, K, Cao, Z, Cinar, R, Fezza, F, Ignatowska-Janlowska, B, Wilkerson, J, Van Gils, N, Hansen, T, Ruben, M, Soethoudt, M, Heitman, L, Kunos, G, Maccarrone, M, Lichtman, A, Pacher, P & Van Der Stelt, M 2016, ' The novel, orally available and peripherally restricted selective cannabinoid CB 2 receptor agonist LEI-101 prevents cisplatin-induced nephrotoxicity ', British Journal of Pharmacology, vol. 173, no. 3, pp. 446-458 . https://doi.org/10.1111/bph.13338
British Journal of Pharmacology, 173(3), 446-58. Wiley-Blackwell
British Journal of Pharmacology, 173(3), 446–458
Background and Purpose Here, we have characterized 3-cyclopropyl-1-(4-(6-((1,1-dioxidothiomorpholino)methyl)-5-fluoropyridin-2-yl)benzyl)imidazolidine-2,4-dione hydrochloride (LEI-101) as a novel, peripherally restricted cannabinoid CB2 receptor agon
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::bfb92a8530a683ea0461f8668983206c
https://doi.org/10.1111/bph.13338
https://doi.org/10.1111/bph.13338
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Mukhopadhyay P; National Institutes of Health, Bethesda, MD, USA., Baggelaar M; Department of Bio-organic Synthesis, Leiden University, Leiden, The Netherlands., Erdelyi K; National Institutes of Health, Bethesda, MD, USA., Cao Z; National Institutes of Health, Bethesda, MD, USA., Cinar R; National Institutes of Health, Bethesda, MD, USA., Fezza F; Department Experimental Medicine & Surgery, Tor Vergata University of Rome, Rome, Italy.; European Center for Brain Research/Santa Lucia Foundation, Rome, Italy., Ignatowska-Janlowska B; Virginia Commonwealth University, Richmond, VA, USA., Wilkerson J; Virginia Commonwealth University, Richmond, VA, USA., van Gils N; Department of Medicinal Chemistry, Leiden University, Leiden, The Netherlands., Hansen T; Department of Bio-organic Synthesis, Leiden University, Leiden, The Netherlands., Ruben M; Department of Bio-organic Synthesis, Leiden University, Leiden, The Netherlands., Soethoudt M; Department of Bio-organic Synthesis, Leiden University, Leiden, The Netherlands., Heitman L; Department of Medicinal Chemistry, Leiden University, Leiden, The Netherlands., Kunos G; National Institutes of Health, Bethesda, MD, USA., Maccarrone M; European Center for Brain Research/Santa Lucia Foundation, Rome, Italy.; Department of Medicine, Campus Bio-Medico University of Rome, Rome, Italy., Lichtman A; Department Experimental Medicine & Surgery, Tor Vergata University of Rome, Rome, Italy., Pacher P; National Institutes of Health, Bethesda, MD, USA., Van der Stelt M; Department of Bio-organic Synthesis, Leiden University, Leiden, The Netherlands.
Publikováno v:
British journal of pharmacology [Br J Pharmacol] 2016 Feb; Vol. 173 (3), pp. 446-58. Date of Electronic Publication: 2016 Jan 15.